EGFR and non-small cell lung carcinoma: The Implementation of Personalized Medicine in NSCLC in Central Europe: EGFR Testing, Histopathology, and Clinical Features (INSIGHT) observational study confirmed that EGFR mutation testing has been implemented in routine clinical practice and that patients with advanced EGFR mutation-positive NSCLC preferentially receive EGFR TKIs as first-line therapy [40].